Variable treatment response in a patient with pyridoxal N phosphate oxidase (PNPO) deficiency- understanding the paradox

• Main Authors: Smilu Mohanlal, Parayil Sankaran Bindu, Sachin Sureshbabu, Suresh Kumar
• Format: Article
• Language: English
• Published: Elsevier 2020-01-01
• Series: Epilepsy & Behavior Reports
• Subjects: Neonatal; Seizures; Pyridoxal N phosphate oxidase (PNPO); Pyridoxine; Riboflavin
• Online Access: http://www.sciencedirect.com/science/article/pii/S2589986420300058

A 6-year-old girl presented with history of infantile onset epileptic encephalopathy and developmental delay. She had polymorphic seizures that were refractory to regular anti-seizure medication. Incomplete control of seizures was achieved on starting pyridoxine, riboflavin and thiamine. Clinical exome sequencing done at 4 years revealed PNPO deficiency with a homozygous mutation in the highly conserved exon 3:c.352G > A p.Gly118R region of the gene. Thereafter, pyridoxine was weaned and pyridoxal phosphate was added with resultant refractory status epilepticus, which necessitated our approach to start pyridoxine and stop pyridoxal phosphate. With two antiseizure medication and three vitamins, she had improved seizure control. At 6 years of age an attempt to wean off riboflavin resulted in break through seizures. After restarting riboflavin along with pyridoxal phosphate, pyridoxine in low doses and two antiseizure medications, the child achieved good seizure control. Though partial responsiveness to pyridoxine with gene mutation in the exon 3: c.352G > A p. Gly118R is known, riboflavin dependence and transient worsening of seizures off pyridoxine has not been described to our knowledge. Our case highlights the importance of identifying the precise gene mutationsequence to properly identify variants relative to individual phenotypic expression, treatment responsivness and need for added vitamin supplementation.